We are live on ! Find out more
STOK icon

Stoke Therapeutics

67 hedge funds and large institutions have $796M invested in Stoke Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 15

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

5% more funds holding

Funds holding: 6467 (+3)

3.24% more ownership

Funds ownership: 102.3%105.54% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

16% less capital invested

Capital invested by funds: $948M → $796M (-$152M)

Holders
67
Holders Change
+3
Holders Change %
+4.69%
% of All Funds
1.48%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
12
Increased
29
Reduced
15
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
76
Bank of Montreal
Ontario, Canada
-$33K -1,155 Closed

STOK Hedge Fund Activity: Q1 2020 in Review

67 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2020, worth a combined $796M — down 16% from $948M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new STOK positions and 9 closed out — a net gain of 3 holders — while 29 added to existing stakes and 15 trimmed.

The largest buyer was Redmile Group, adding an estimated $28.3M. The largest seller was Janus Henderson Group, cutting an estimated $14.5M.

  • 67 institutional investors held Stoke Therapeutics (STOK) as of Q1 2020, up from 64 in Q4 2019.
  • Funds reported $796M of Stoke Therapeutics stock for Q1 2020, down 16% quarter-over-quarter.
  • 12 funds opened new Stoke Therapeutics positions in Q1 2020 and 9 closed out, a net change of +3 holders.
  • The largest Stoke Therapeutics buyer in Q1 2020 was Redmile Group, an estimated $28.3M added.
  • The largest Stoke Therapeutics seller in Q1 2020 was Janus Henderson Group, an estimated $14.5M sold.

Based on aggregated 13F filings for Q1 2020.